FY2026 EPS Forecast for Perspective Therapeutics Lowered by Analyst

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Analysts at Brookline Capital Markets decreased their FY2026 earnings per share estimates for shares of Perspective Therapeutics in a research report issued on Tuesday, November 10th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will earn ($1.00) per share for the year, down from their prior forecast of ($0.99). The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.98) per share. Brookline Capital Markets also issued estimates for Perspective Therapeutics’ Q4 2026 earnings at ($0.25) EPS.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million.

A number of other brokerages have also weighed in on CATX. Piper Sandler lowered their target price on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. BMO Capital Markets reiterated an “outperform” rating on shares of Perspective Therapeutics in a research report on Friday, October 30th. Bank of America reduced their price target on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. Wedbush reissued an “outperform” rating and set a $7.00 price objective (down from $9.00) on shares of Perspective Therapeutics in a report on Tuesday. Finally, Royal Bank Of Canada cut shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price objective for the company from $14.00 to $4.00 in a research report on Monday, October 26th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Perspective Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $10.10.

Perspective Therapeutics Trading Up 4.9%

Perspective Therapeutics stock opened at $0.83 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 6.61. The business’s fifty day moving average is $2.20 and its two-hundred day moving average is $3.46. Perspective Therapeutics has a 52 week low of $0.78 and a 52 week high of $6.16.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Voya Investment Management LLC lifted its stake in shares of Perspective Therapeutics by 34.4% during the third quarter. Voya Investment Management LLC now owns 453,650 shares of the company’s stock valued at $1,248,000 after acquiring an additional 116,149 shares during the period. Russell Investments Group Ltd. boosted its holdings in Perspective Therapeutics by 53.1% in the third quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock valued at $168,000 after acquiring an additional 21,150 shares during the last quarter. Provenance Wealth Advisors LLC bought a new position in Perspective Therapeutics in the third quarter valued at about $44,000. Auctus Advisors LLC increased its position in Perspective Therapeutics by 83.6% in the third quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock worth $103,000 after purchasing an additional 17,015 shares during the period. Finally, Taylor & Morgan Wealth Management LLC increased its position in Perspective Therapeutics by 30.3% in the third quarter. Taylor & Morgan Wealth Management LLC now owns 86,000 shares of the company’s stock worth $236,000 after purchasing an additional 20,000 shares during the period. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.